Actively Recruiting

Age: 60Years +
All Genders
NCT06566170

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Led by Eli Lilly and Company · Updated on 2025-10-09

6250

Participants Needed

1

Research Sites

434 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

CONDITIONS

Official Title

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Who Can Participate

Age: 60Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Under care for presumed mild cognitive impairment or mild dementia stage of Alzheimer's disease
  • Telephone Interview for Cognitive Status (TICS) score of 21 or higher
  • Presence of amyloid beta pathology supported by biomarker results within 12 months before study entry
  • Have a reliable study partner in frequent contact and available by phone every 6 months
  • Willing to provide access to electronic health records for study duration
Not Eligible

You will not qualify if you...

  • Prior ischemic or hemorrhagic stroke causing inability to perform one or more basic daily activities independently
  • Current or recent serious or unstable illness that may interfere with study completion (e.g., life expectancy under 36 months, need for long-term institutional care, serious psychiatric illness)
  • Currently enrolled or planning to enroll in another investigational product clinical trial
  • Contraindications to donanemab, MRI, or amyloid PET tracers (for donanemab group only)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Rehabilitation & Neurological Services

Huntsville, Alabama, United States, 35805-4046

Actively Recruiting

Loading map...

Research Team

T

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease | DecenTrialz